Restrictions to the use of Esmya (ulipristal acetate) for the symptoms of uterine fibroids and the requirement to check liver function

The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a letter for healthcare professionals - Esmya (ulipristal acetate) for symptoms of uterine fibroids: restrictions to use and requirement to check liver function before, during and after treatment. This provides information on restrictions which replace the temporary safety measures introduced in February 2018.

The emergency contraceptive ellaOne also contains ulipristal acetate (single-dose, 30mg). No cases of serious liver injury have been reported with ellaOne since its EU authorisation in 2009, and there are no concerns with this medicine at this time.

Further details of the new restrictions and actions to take are available in the letter for healthcare professionals.